Sehayek Ephraim, Hazen Stanley L
Department of Cell Biology, Cleveland Clinic, Ohio 44195, USA.
Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1296-7. doi: 10.1161/ATVBAHA.108.165803. Epub 2008 Apr 17.
We examined the effect of ezetimibe, a cholesterol absorption (CA) inhibitor, and genetic determinants of CA on reverse cholesterol transport (RCT) from subcutaneously injected macrophages using a new dual isotope label technique.
Treatment of C57BL/6J mice with ezetimibe decreased dietary CA by 86% and increased RCT from peripheral tissue macrophages (PTM) by 6-fold (P<0.0001). Moreover, congenic 14DKK mice with a modest 41% decrease in dietary CA displayed a 67% increase in RCT from PTM (P<0.007).
These findings indicate that pharmacological and genetic modifiers of cholesterol absorption are major determinants of reverse cholesterol transport from peripheral tissue macrophages.
我们使用一种新的双同位素标记技术,研究了胆固醇吸收(CA)抑制剂依泽替米贝以及CA的遗传决定因素对皮下注射巨噬细胞逆向胆固醇转运(RCT)的影响。
用依泽替米贝治疗C57BL/6J小鼠可使膳食CA降低86%,并使外周组织巨噬细胞(PTM)的RCT增加6倍(P<0.0001)。此外,膳食CA适度降低41%的同源14DKK小鼠,其PTM的RCT增加了67%(P<0.007)。
这些发现表明,胆固醇吸收的药理学和基因修饰剂是外周组织巨噬细胞逆向胆固醇转运的主要决定因素。